<?xml version="1.0" encoding="UTF-8"?>
<p>According to the US Food and Drug Administration (FDA) guidelines, investigators in the US wishing to study the use of convalescent plasma in a clinical trial should submit requests to the FDA for investigational use under the traditional investigational new drug (IND) regulatory pathway [
 <xref rid="B35" ref-type="bibr">35</xref>]. The suggested patient eligibility criteria are as follows: (1) Laboratory confirmed COVID-19; (2) severe or immediately life-threatening disease; and (3) Informed consent provided by the patient or a healthcare proxy.
</p>
